{
    "clinical_study": {
        "@rank": "47067", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "EPODURE Biopump secreting EPO (18-25 IU/Kg/day)"
            }, 
            {
                "arm_group_label": "Gtoup B", 
                "arm_group_type": "Experimental", 
                "description": "EPODURE Biopump secreting EPO (35-45 IU/Kg/day)"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "EPODURE Biopump secreting EPO (55-65 IU/Kg/day)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to assess safety and to evaluate the biologic activity of\n      EPODURE treatment."
        }, 
        "brief_title": "EPODURE Biopump Treatment for Anemia in CKD and ESRD", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "End Stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I-II, open-label study. Each patient will receive targeted dose of EPO\n      delivered via EPODURE Biopumps. The targeted doses will be determined according to 3 cohorts\n      as follows: Group A (18-25 IU/Kg/day), Group B (35-45 IU/Kg/day), Group C (55-65 IU/Kg/day).\n      The objective is to evaluate safety and biologic activity of EPODURE treatment when\n      maintaining Hb levels within the target range of 9-11 g/dl. Biological activity assessments\n      will include duration of EPODURE secretion as measured by serum EPO levels above baseline"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male or female subjects between 18 to 80 years of age at the time of screening\n             visit.\n\n          2. ESRD: Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on\n             hemodialysis treatment for at least 6 months. Average Hb during last 2-3 months\n             between 9 to 11g/dL, CKD: Subject with Anemia due to Chronic Renal Failure CKD stage\n             3-4. Estimated GFR of 15-60 ml/min. previously or currently diagnosed with Hb level\n             of 11 g% or less.\n\n          3. Kt/V >1 (not relevant for CKD patients)\n\n          4. INR not higher than 1.2\n\n          5. Subjects who are clinically stable.\n\n          6. Serum albumin >3.5\n\n          7. Subjects with adequate iron stores (transferrin saturation > 20.0% and/or ferritin\n             >100 ng/ml).\n\n          8. Signed written informed consent to participate in the study.\n\n        Exclusion Criteria:\n\n          1. Uncontrolled hypertension\n\n          2. Subjects who receive oral anti-coagulation treatment\n\n          3. Subjects who receive Acetyl Salicylic Acid (ASA) above 325 mg/day or patients who\n             receive ASA treatment between 100mg/d and 325 mg/d who cannot discontinue it for 1\n             week prior to each EPODURE procedure\n\n          4. Patients currently receiving injections of long-acting Erythropoiesis Stimulating\n             Agents (ESA) (e.g. Aranesp, Mircera) a patient on long acting ESA can be switched to\n             a short acting preparation.\n\n          5. Congestive heart failure (New York Heart Association functional class III or IV).\n\n          6. Grand mal seizures within 2 years of the screening visit.\n\n          7. Clinical evidence of severe hyperparathyroidism as defined by PTH levels of > 10\n             times the upper normal limits.\n\n          8. Major surgery within 12 weeks of the screening visit.\n\n          9. Systemic hematologic diseases\n\n         10. Current systemic infection, active inflammatory disease, or malignancy under active\n             treatment.\n\n         11. Subjects known to have tested positive at any time in the past for antibodies to\n             erythropoietic proteins.\n\n         12. Subject has history of malignancy within the past 2 years prior to the screening\n             visit, with the exception of basal cell carcinoma.\n\n         13. Subjects with other concurrent severe and/or uncontrolled medical condition which\n             could compromise participation in the study\n\n         14. Subject is currently enrolled in, or has not yet completed a period of at least 30\n             days or five half-lives of the investigational drug whichever is longer, since ending\n             other investigational device or drug trial(s) prior to Screening phase.\n\n         15. Psychiatric, addictive, or any other disorder that compromises ability to give truly\n             informed consent for participation in this study.\n\n         16. Female subjects of child-bearing potential and males that do not agree to use\n             acceptable methods of contraception during the study.\n\n         17. Pregnant and lactating female subjects.\n\n         18. Chronic alcoholic or drug abuse subjects.\n\n         19. Steroid or other immunosuppressive treatment (other than topical or inhaled\n             steroids).\n\n         20. Subjects unwilling or unable to comply with the study procedures.\n\n         21. ESRD: EPO Na\u00efve subjects.\n\n         22. Known sensitivity to Gentamycin and Amphotericin\n\n         23. History of chronic or active Hepatitis B and/or C infection or positive serology at\n             screening and known positive HIV or positive serology at screening.\n\n         24. Subject had blood transfusion within 84 days prior to Screening visit.\n\n         25. Subject has a planned renal transplantation.\n\n         26. Subject has a temporary or permanent hemodialysis catheter.\n\n         27. Refer to the USPI - Depo-Medrol - Methylprednisolone Acetate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117427", 
            "org_study_id": "MG-EP-RF-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Gtoup B", 
                    "Group C"
                ], 
                "description": "Erythropoietin secreted by EPODURE Biopumps", 
                "intervention_name": "EPODURE Biopump", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Gtoup B", 
                    "Group C"
                ], 
                "intervention_name": "EPO", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 27, 2014", 
        "location": {
            "contact": {
                "email": "dorons@tlvmc.gov.il", 
                "last_name": "Doron Schwartz, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel"
                }, 
                "name": "Tel Aviv Sourasky Medical Center"
            }, 
            "investigator": {
                "last_name": "Doron Schwartz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "3", 
        "official_title": "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE Biopump", 
        "overall_contact": {
            "email": "shany@medgenics.com", 
            "last_name": "Shany Blum, MD PhD", 
            "phone": "+972-54-5331773"
        }, 
        "overall_official": {
            "affiliation": "Medgenics Inc.", 
            "last_name": "Shany Blum, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ministry of Health", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics profiles of EPODURE produced EPO", 
            "safety_issue": "No", 
            "time_frame": "up to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medgenics Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Medgenics Medical Israel Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medgenics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}